vimarsana.com

Page 6 - Insulet Omnipod News Today : Breaking News, Live Updates & Top Stories | Vimarsana

FDA clears Insulet Omnipod 5 for children two years and older

Insulet (Nasdaq:PODD) announced today that the FDA cleared its Omnipod 5 for individuals aged two years and older with type 1 diabetes.

The biggest stories from American Diabetes Association Scientific Sessions

Studies supporting technology from Abbott and Medtronic, plus an interview with Dexcom's CEO highlight some big news out of ADA 2022.

Insulet s Omnipod 5 improves glycemic outcomes in very young children

Insulet (Nasdaq:PODD) announced data supporting the use of its Omnipod 5 automated insulin delivery system in young children.

Why DexCom Stock Is Jumping Today | The Motley Fool

The company confirmed that it isn't in merger discussions with Insulet.

Bigfoot Biomedical adds former Insulet VP as chief commercial officer

Bigfoot Biomedical announced today that it appointed former Insulet executive Matt Rainville as its chief commercial officer.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.